SAN DIEGO – May 7, 2013 — OncoSec Medical Inc. (OTCBQ: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the Sachs Cancer Bio Partnering Forum at the Westin Copley Place in Boston, Massachusetts on Tuesday, May 21 at 2:05 PM ET.
In addition, Mr. Dhillon will be participating in a panel discussion titled “Immunotherapies & Cancer Vaccines” to be held on Tuesday, May 21 at 4:00 PM ET. The panel will be chaired by Florian Schodel, CEO, Philimmune LLC and Mara Goldstein, Senior Analyst, Cantor Fitzgerald.
About the Sachs Cancer Bio Partnering Forum
The Sachs Cancer Bio Partnering Forum is a two-day conference designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. Approximately 300 delegates are expected. There will be presentations by various research institutes, patient advocacy groups, pharmaceutical companies on partnering and biotech’s seeking licensing/investment. For more information, visit: http://www.sachsforum.com/boston13/